Clinical trial
A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody，in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment
NCT02211443 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody，in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment
- Lead sponsor
- Sinocelltech Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- January 31, 2015
- Completion date
- December 31, 2015
- Enrollment
- 21 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic colorectal cancer